The role of heart rate variability in acute mountain sickness: A meta-analysis

心率变异性在急性高原反应中的作用:一项荟萃分析

阅读:1

Abstract

BACKGROUND: Acute mountain sickness (AMS) is associated with symptoms arising from an individual's failure to acclimatize to high-altitude environments characterized by hypobaric hypoxia. Heart rate variability (HRV) has been proposed as a potential predictor of AMS, but results from individual studies have been inconsistent. Therefore, this study investigated HRV before and after ascent to provide a more comprehensive review of the relationship between HRV and AMS. METHODS: We conducted a systematic search of MEDLINE, PubMed, and Google Scholar from inception to August 2023. Studies measuring HRV in relation to AMS were included. The quality of studies was assessed using the Newcastle-Ottawa scale. RESULTS: Initially, 153 trials were identified through our search strategy. Seven studies met the inclusion criteria, comprising a total of 329 participants. Before ascent, individuals who developed AMS showed significantly higher percentage of successive R-R intervals that differ by more than 50 ms compared with those who did not develop AMS (standardized mean difference = 0.40, 95% confidence interval: [0.11 to 0.69]). After ascent, the AMS group exhibited significantly lower standard deviation of normal-to-normal R-R intervals (standardized mean difference = -0.41, 95% confidence interval: [-0.69 to -0.13]). Other HRV parameters, including low-frequency and high-frequency power, showed trends toward lower values in the AMS group but did not reach statistical significance. CONCLUSION: This meta-analysis proves that certain HRV parameters, particularly percentage of successive R-R intervals that differ by more than 50 ms before ascent and standard deviation of normal-to-normal R-R intervals after ascent, may be associated with AMS development. These findings suggest that HRV analysis could potentially be used as a tool for predicting and monitoring AMS. However, further research is needed to establish definitive clinical guidelines.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。